LLY

Eli Lilly & Co
D

LLY

Arincen83/100B

If you had invested in Eli Lilly & Co ago, it would be worth $20,499 today, against $3,836 in SPY and $5,891 in QQQ.

ArincenArincen ScoreBeta

83/100

Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.

Profitability10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Cash8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Valuation8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Growth10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Financial strength8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Shareholders6

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Figures to FY2025; the price as of today.

Eli Lilly & Co key facts

Style
Growth stock · 9.5/10Growth 9.5 · Value 2.5 · Dividend 2.0
Day range
1,341.61 – 1,381.32
52-week range
850.51 – 1,475.25
Market capitalization
1.27T USD
P/E
43.74
PEG ratio
1.68
EPS
30.89
Div Yield
0.51%
EPS growth forecast (FY2026)
+46.5%
Volume
99
Beta
0.45
ESG score
71.2/100Environment 82 · Social 62 · Governance 69
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
David A. Ricks
Employees
50K
Website
lilly.com
IPO date
1 Jun 1972

Eli Lilly & Co earnings

Next earnings · Q4 FY2026
EPS estimate
11.23 USD
Revenue estimate
24.61B USD
Last quarter · Q3 FY2026
EPS7.48Beat +31.0%Revenue24.40BBeat +8.0%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q1 FY202710.93——+27.89%23.62B——+19.31%
Q4 FY202611.23——+48.94%24.61B——+27.55%
Q3 FY20265.717.48+31.00%+6.55%22.58B24.40B+8.03%+38.61%
Q2 FY20266.408.38+30.94%+32.81%20.82B22.97B+10.33%+47.67%
Q1 FY20266.978.55+22.67%+155.99%17.82B19.80B+11.11%+55.55%
Q4 FY20256.917.54+9.12%+41.73%17.94B19.29B+7.51%+42.56%
Q3 FY20255.697.02+23.37%+494.92%16.05B17.60B+9.64%+53.87%
Q2 FY20255.606.31+12.68%+60.97%14.70B15.56B+5.80%+37.64%

Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved

Eli Lilly & Co analyst forecast

12-month price target
1,442.44 USD
+6.75%

Analysts' 1-year price targets range from 940.00 to 1,650.00, with an average of 1,442.44.

Past year
1-year forecast
Strong sellStrong buy
Strong buy
22 ratings
Buy
21
Hold
0
Sell
1

12-month price target

Highest target1,650.00
Average target1,442.44
Lowest target940.00
Current price1,351.22

Eli Lilly & Co valuation

Price to earnings ratio (TTM)
43.74
Forward P/E (FY2026)
38.11
Price to sales (TTM)
14.70
Price to book
31.56
EV / EBITDA (TTM)
29.40

Capital structure

Market capitalization
1.27T USD
+
Total debt
49.50B USD
−
Cash and short-term investments
4.89B USD
=
Enterprise value
1.32T USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)23.32————
FY2027 (est.)26.6623.32———
FY2026 (est.)38.1126.66———
Now (TTM)43.7427.5914.7031.5629.40
FY202546.5830.3214.8136.3731.56
FY202465.6532.7215.4448.9938.58
FY202399.9945.5815.3648.6763.81
FY202252.7958.7111.5630.9839.73
FY202144.9136.168.8527.9032.77

Eli Lilly & Co against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Johnson & Johnson, AbbVie, Merck & Co., Amgen, Gilead Sciences, and Pfizer, the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Below its median43.7
    33.1144.0
  • Gross marginHighest in 5 years83.0%
    74.2%83.0%
    Against its peers: 1 of 7Peers' median 71.4%
  • Operating marginHighest in 5 years45.6%
    22.4%45.6%
    Against its peers: 1 of 7Peers' median 27.5%
  • Net marginHighest in 5 years31.7%
    15.4%31.7%
    Against its peers: 1 of 7Peers' median 24.6%
  • Return on equityHighest in 5 years77.8%
    48.6%77.8%
    Against its peers: 2 of 6Peers' median 34.7%
  • Free cash flow marginAt its median13.8%
    2.3%19.0%
    Against its peers: 7 of 7Peers' median 21.5%
  • Revenue growthHighest in 5 years44.7%
    0.8%44.7%
    Against its peers: 1 of 7Peers' median 4.2%
  • EPS growthAbove its median96.0%
    -15.9%101.9%
    Against its peers: 2 of 7Peers' median 48.1%
  • Debt to EBITDALowest in 5 years1.34×
    1.34×2.94×
    Against its peers: 2 of 7Peers' median 2.53×
  • Current ratioHighest in 5 years1.58
    0.941.58
    Against its peers: 1 of 7Peers' median 1.15

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

Eli Lilly & Co growth and profitability

Revenue (TTM)
86.46B USD
Net income (TTM)
27.58B USD
Gross margin
83.63%
Operating margin
46.07%
Net margin
31.90%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY202565.18B+44.70%20.64B+94.90%83.04%45.56%31.67%31.69B+68.52%
FY202445.04B+32.00%10.59B+102.08%81.31%37.83%23.51%18.81B+119.51%
FY202334.12B+19.56%5.24B-16.08%79.25%31.61%15.36%8.57B-1.07%
FY202228.54B+0.79%6.24B+11.88%76.77%24.97%21.88%8.66B+7.68%
FY202128.32B+15.40%5.58B-9.88%74.18%22.45%19.71%8.04B-9.77%

Eli Lilly & Co revenue breakdown

By product

FY2025
Product: 93.5%Collaboration and Other Revenue: 6.5%93.5%Product6.5%Collaboration and Other Revenue
SegmentRevenueShare of revenueChange on the year
Product60.96B93.5%+49.6%
Collaboration and Other Revenue4.22B6.5%-1.7%

By region

FY2025
United States: 66.7%Europe: 17.7%Non-US: 9.3%Japan: 3.3%China: 3.0%66.7%United States17.7%Europe9.3%Non-US3.3%Japan3.0%China
RegionRevenueShare of revenueChange on the year
United States43.48B66.7%+43.1%
Europe11.56B17.7%+67.0%
Non-US6.06B9.3%+41.8%
Japan2.13B3.3%+17.5%
China1.95B3.0%+17.5%

How Eli Lilly & Co makes its money

Product60.96B 93.5%
Collaboration and Other Revenue4.22B 6.5%
Revenue65.18B 100.0%
Cost of revenue11.05B 17.0%
Gross profit54.13B 83.0%
Research and development13.34B 20.5%
Selling and administration11.09B 17.0%
Operating income29.70B 45.6%
Tax5.09B 7.8%
Other expense3.97B 6.1%
Net income20.64B 31.7%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

Eli Lilly & Co dividends

Annual dividend
6.92 USD
Dividend yield (indicated)
0.51%
Payout ratio
22.40%
Years of dividend growth
12
Frequency
Quarterly
Next payment
1.73 USD
Last ex-dividend date
13 Nov 2026
Next payment date
10 Dec 2026

Dividends per share

Year2025202420232022202120202019201820172016
Dividends per share6.005.204.523.923.402.962.582.252.082.04

Eli Lilly & Co financial health

Cash and short-term investments
4.89B USD
Total debt
49.50B USD
Net cash
-44.62B USD
Free cash flow (TTM)
19.66B USD
Current ratio
1.39
Debt to equity
1.23
Piotroski score
7 / 9
Altman Z-score
9.55

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY20257.27B42.50B8.97B
FY20243.42B33.64B3.76B
FY20232.93B25.23B792.50M
FY20222.21B16.24B4.60B
FY20213.91B16.88B5.39B

Eli Lilly & Co ownership

Institutions
73.53%
Institutional holders
4,233 (-584)
Free float
90.13%

Who owns the shares

Institutions 73.5% Others 26.5%
As of 30 Sept 2026

Shares free to trade

Free float 847.86M shares ·90.1% Closely held 92.88M shares ·9.9%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q4 20260112.22K46.89K
Q3 2026031.09K15.16K
Q2 202603128.9618.33K
Q1 2026031171.72K401.20K

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2025898.00M898.00M-0.67%
FY2024900.61M904.06M+0.09%
FY2023899.38M903.28M-0.15%
FY2022901.74M904.62M-0.77%
FY2021906.96M911.68M-4.69%

Source: Financial Modeling Prep

Signals
buy
LLY
LLYEli Lilly & Co @823.59
2025-03-12 08:30
LLY@823.59 Chart
Profit
5,008.00
USD
12.16%
buy
LLY
LLYEli Lilly & Co @736.03
2025-08-27 07:11
LLY@736.03 Chart
Profit
4,494.00
USD
12.21%
buy
LLY
LLYEli Lilly & Co @737.88
2025-04-07 10:10
LLY@737.88 Chart
Profit
7,313.50
USD
19.82%
buy
LLY
LLYEli Lilly & Co @844.23
2025-02-17 11:21
LLY@844.23 Chart
Profit
3,513.00
USD
8.32%
More
Related Instruments News

Title: Eli Lilly & Co

Sector: Healthcare
Industry: Drug Manufacturers - General
Eli Lilly and Company researches, develops, manufactures, and sells pharmaceutical products for humans and animals. This American multinational pharmaceutical firm has its company headquarters in Indianapolis, Indiana. It also has branch locations in 18 countries around the world. Its products find their way into markets in roughly 125 countries globally. Some of the firm’s marquee pharmaceutical brands include the clinical depression drug Prozac and the antipsychotic medication Zyprexa. The company has been ranked in the top 150 firms of the Fortune 500 list of top American companies by revenue.

Common questions about Eli Lilly & Co stock